Cambridge Cognition Interim Earnings Report

Cambridge Cognition EPS Results

• Actual EPS: -GBX 2.40
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Cambridge Cognition Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Cambridge Cognition Announcement Details

• Quarter: Interim
• Date: 9/2/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Cambridge Cognition (LON:COG), a neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB digital cognitive assessment platform for drug development by enabling pharmaceutical companies to take new therapeutics from preclinical consultancy to pivotal studies and approval, as well as supports sponsors to enhance recruitment, develop safe and effective treatments, and enhance research and development efficiency. It also provides CANTAB Connect Research, a proprietary platform that provides insights into behaviours, underlying brain circuits, and measurement of digital cognitive biomarkers; CANTAB Mobile, a touchscreen assessment of memory, mood, and functional status to detect the earliest signs of clinically relevant memory problems; CANTAB Insight to assess cognitive health; and CANTAB BrainHealth for assessing workplace wellbeing. In addition, the company offers electronic questionnaires and scales, a digital bespoke questionnaire; NeuroVocalix, a voice analysis platform to analyze voice to assess neurological change; cognition kit, a high frequency testing kit to detect changes over time and day-to-day cognition with short regular tests using patients' own devices. Cambridge Cognition Holdings Plc was incorporated in 2012 and is based in Cambridge, the United Kingdom.